NasdaqGM:CLSD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Clearside Biomedical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLSD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-11.4%

CLSD

0.6%

US Pharmaceuticals

0.7%

US Market


1 Year Return

35.8%

CLSD

16.3%

US Pharmaceuticals

20.1%

US Market

Return vs Industry: CLSD exceeded the US Pharmaceuticals industry which returned 11.8% over the past year.

Return vs Market: CLSD exceeded the US Market which returned 17.1% over the past year.


Shareholder returns

CLSDIndustryMarket
7 Day-11.4%0.6%0.7%
30 Day-5.2%4.5%6.4%
90 Day-23.5%2.5%20.1%
1 Year35.8%35.8%19.2%16.3%22.6%20.1%
3 Year-77.0%-77.0%32.8%23.0%45.1%35.7%
5 Yearn/a35.4%19.8%79.7%60.3%

Price Volatility Vs. Market

How volatile is Clearside Biomedical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clearside Biomedical undervalued compared to its fair value and its price relative to the market?

43.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CLSD ($1.63) is trading below our estimate of fair value ($2.9)

Significantly Below Fair Value: CLSD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CLSD is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: CLSD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLSD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLSD is overvalued based on its PB Ratio (10.1x) compared to the US Pharmaceuticals industry average (3.2x).


Next Steps

Future Growth

How is Clearside Biomedical forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-17.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLSD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLSD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLSD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLSD's revenue (38.6% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: CLSD's revenue (38.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLSD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Clearside Biomedical performed over the past 5 years?

-17.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLSD is currently unprofitable.

Growing Profit Margin: CLSD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CLSD is unprofitable, and losses have increased over the past 5 years at a rate of 17.5% per year.

Accelerating Growth: Unable to compare CLSD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLSD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.1%).


Return on Equity

High ROE: CLSD has a negative Return on Equity (-251.09%), as it is currently unprofitable.


Next Steps

Financial Health

How is Clearside Biomedical's financial position?


Financial Position Analysis

Short Term Liabilities: CLSD's short term assets ($16.3M) exceed its short term liabilities ($9.2M).

Long Term Liabilities: CLSD's short term assets ($16.3M) exceed its long term liabilities ($1.3M).


Debt to Equity History and Analysis

Debt Level: CLSD's debt to equity ratio (13.6%) is considered satisfactory.

Reducing Debt: CLSD's debt to equity ratio has reduced from 194.3% to 13.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLSD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CLSD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Clearside Biomedical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLSD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLSD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLSD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLSD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLSD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

George Lasezkay (68 yo)

1.33yrs

Tenure

US$1,059,192

Compensation

Dr. George M. Lasezkay, Pharm.D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since January 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive ...


CEO Compensation Analysis

Compensation vs Market: George's total compensation ($USD1.06M) is above average for companies of similar size in the US market ($USD589.03K).

Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
George Lasezkay
President1.33yrsUS$1.06m0.19%
$ 138.3k
Charles Deignan
Chief Financial Officer8.58yrsUS$661.21k0.28%
$ 205.1k
Jenny Kobin
Head of Investor Relationsno datano datano data
Leslie Zacks
General Counsel1.92yrsno datano data
Rick McElheny
Vice President of Corporate Development2.58yrsno datano data
Thomas Ciulla
Chief Medical Officer & Chief Development Officer1.83yrsno data0.32%
$ 236.4k

1.9yrs

Average Tenure

54.5yo

Average Age

Experienced Management: CLSD's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
George Lasezkay
President1.33yrsUS$1.06m0.19%
$ 138.3k
Christy Shaffer
Independent Director8.58yrsUS$64.03k0.0098%
$ 7.2k
Jeffrey Edwards
Independent Director1.92yrsUS$70.03kno data
Clay Thorp
Independent Director8.58yrsUS$65.03k0.018%
$ 13.0k
Carl Regillo
Member of Scientific Advisory Board0.33yrno datano data
William Humphries
Independent Chairman of the Board2.5yrsUS$114.53kno data
David Boyer
Member of Scientific Advisory Board0.33yrno datano data
Nancy Hutson
Independent Director0.33yrno data0.011%
$ 8.1k
Peter Kaiser
Member of Scientific Advisory Board0.33yrno datano data
Richard Croarkin
Independent Director4.5yrsUS$78.03kno data
Nancy Holekamp
Member of Scientific Advisory Board0.33yrno datano data
David Brown
Member of Scientific Advisory Board0.33yrno datano data

1.1yrs

Average Tenure

62yo

Average Age

Experienced Board: CLSD's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CLSD insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.8%.


Top Shareholders

Company Information

Clearside Biomedical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clearside Biomedical, Inc.
  • Ticker: CLSD
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$73.136m
  • Shares outstanding: 44.87m
  • Website: https://www.clearsidebio.com

Number of Employees


Location

  • Clearside Biomedical, Inc.
  • 900 North Point Parkway
  • Suite 200
  • Alpharetta
  • Georgia
  • 30005
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLSDNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2016
CLMBST (Boerse-Stuttgart)YesCommon StockDEEURJun 2016

Biography

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a tr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/12 23:51
End of Day Share Price2020/08/12 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.